Global Non-Small Cell Lung Cancer Treatment Market Report and Forecast 2025-2034

Non-Small Cell Lung Cancer Market: Introduction

Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer. There is an abnormal growth of cancerous cells in the lung tissues. This cancer is coined as “non-small” due to the presence of larger abnormal cells, in comparison to small cell lung cancer. The three types of non-small cell lung cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

The signs and symptoms of non-small cell lung cancer consist of cough, shortness of breath, chest pain, hoarseness, wheezing, loss of appetite, and difficulty in swallowing and breathing.

The exact cause of non-small cell lung cancer is unknown, but the disease is set to be triggered by several risk factors, including smoking, air pollution, and exposure to certain metals, mineral dust, asbestos, radon, and harmful radiations. This type of cancer can also occur because of associated disorders, such as chronic obstructive pulmonary disorder, pulmonary fibrosis, and HIV or AIDS.

The diagnosis of non-small cell lung cancer is done with the help of laboratory tests and chest X-rays. CT scans, biopsy, and sputum cytology are the confirmatory diagnostic measures used to analyse the anatomy of the lungs and other respiratory organs. Bronchoscopy and thoracoscopy are the procedures used to examine the airways and chest.

The non-small cell lung cancer consists of several stages, depending on the spreading of the cancerous cells. The treatment strategies are incorporated based on the different stages- stage 0, stage I, stage II, stage III, and stage IV. NSCLC accounts for nearly 85 per cent of all lung cancers prevalent across the world.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Non-Small Cell Lung Cancer Market Segmentations

Non-Small Cell Lung Cancer Treatment Market Scenario

Increasing prevalence of non-small cell lung cancer has been driving the market growth. NSCLC accounts for 80-85 per cent of all the prevalent lung cancer cases globally. This can be attributed to the increased demand for the non-small cell lung cancer treatment market.

The growing demand for diagnostics and therapeutics has stimulated the focus of big pharmaceutical companies towards constant research and innovation for advanced treatment care, bolstering the efficacy of the existing therapeutics. The rising investments by the key players in the research and development activities and favouring government initiatives are anticipated to fuel the market growth further.

The market growth can further be accelerated by the increasing number of diagnoses and improving healthcare-related awareness. The entry of advanced and novel therapeutic interventions is also expected to aid the expansion of the non-small cell lung cancer treatment market. The introduction of targeted therapies and sophisticated treatment facilities has led to significant advancements in healthcare.

North America is anticipated to dominate the regional markets owing to the increase in the patient pool, a growing number of chain smokers, and the existence of advanced immunotherapies. Europe is also expected to hold a significant share in the non-small cell lung cancer treatment market because of the rising adoption of advanced therapeutics and improved awareness.

Non-Small Cell Lung Cancer Treatment Market Therapeutic Landscape

The treatment of non-small cell lung cancer treatment is dependent on the extent of distribution of cancerous cells. There are different treatment regimens based on the stage of cancer and the affected areas of the body. Surgery is the first-line treatment for most of the diagnosed cases. In these procedures, the tumour is removed, including the surrounding healthy tissue around that tumour.

Radiofrequency ablation and radiation therapy are also used for surgery-intolerant patients. In radiofrequency ablation, the surgeon eradicates the cancerous cells by heating the tumour with high-energy radio waves. Radiation therapy is based on the killing of cancerous cells with the help of powerful X-ray beams.

Chemotherapy is the most commonly used procedure for the management of non-small cell lung cancer. This therapy adheres to the further growth of the cancerous cells and hence, stops the further spread of cancer. Chemotherapy can be given through oral and intravenous routes.

With extensive research, targeted drug therapies have been discovered and have improved therapeutic effects. The targeted drug therapies act by specific targeting abnormal cells without hampering the healthy cells. The two commonly used targeted therapies are tyrosine inhibitors and monoclonal antibodies.

Immunotherapy is another therapeutic procedure based on the application of certain drugs to boost the strength of the immunity system. This assists the immune system to identify its healthy cells and cancerous cells. The drugs used in immunotherapy are called checkpoint inhibitors and include atezolizumab, pembrolizumab, and cemiplimab. The increased demand for these targeted immunotherapies has attributed to the growth of the non-small cell lung cancer treatment market growth during the forecast period.

Non-Small Cell Lung Cancer Treatment Market- Clinical Trials Landscape- Novel Therapeutic Products Under Pipeline

The recent discovery of novel targeted therapies has been of major interest to experts, researchers, and key players. Tremendous efforts and intensive research and development are under process for immunotherapy and tyrosine kinase inhibitors. Despite the discovery of many novel oncological agents, the focus of the scientists is to explore the optimisation of new therapeutic interventions into clinical practice.

AstraZeneca, a key market trial, has funded the clinical trials of the novel drug, Osimertinib. The ongoing ADAURA trials for this drug have shown some promising effects for the treatment of early-stage EGFRm non-small cell lung cancer. The drug has also reduced the chances of disease recurrence in patients during clinical studies.

Sapanisertib, an investigational drug, discovered by Calithera Biosciences has been granted fast-track approval by the FDA for the treatment of non-small cell lung cancer. This drug is specifically approved for the treatment of the mutated nuclear erythroid 2-related factor tumours and is still under further investigation. This type of mutation is prevalent in around 15 per cent of the patients suffering from metastatic squamous non-small cell lung cancer.

GlaxoSmithKline, a major company, is performing Phase III clinical trials for the Jemperli drug. This drug has shown positive effects in the phase II trials, and henceforth, progressed to the advanced stages for further assessment.

Recently, FDA has given fast-track approval to the combination therapy of Pembrolizumab and Eftilagimod Alpha for the treatment of the first line of non-small cell lung cancer. This will stimulate the therapeutic prospects in the field of immunotherapy and will provide more effective and durable solutions to the patients.

The significant advancements have led to the discovery of many novel therapeutic products, once approved, these drugs are anticipated to bolster the non-small cell lung cancer treatment market growth and development.

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the non-small cell lung cancer treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Genentech, Inc. (F. Hoffmann-La Roche Ltd)

• Eli Lilly and Company

• Celgene Corporation (Bristol-Myers Squibb Company)

• Pfizer Inc.

• AstraZeneca

• Sanofi

• Novartis AG

• Astellas Pharma Inc.

• Boehringer Ingelheim International GmbH

• Merck & Co. Inc.

• Takeda Pharmaceutical Company Limited

• Clovis Oncology

• Johnson & Johnson Services, Inc.

• Teva Pharmaceutical Industries Ltd.